Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that it bought back 22,400 H shares on 27 May 2026 via on-market transactions. The repurchases were executed at prices ranging between HKD 27.52 and HKD 29.48 per share, with a volume-weighted average cost of HKD 28.18, bringing total cash outlay to HKD 0.63 million.

Following the transaction, the company’s outstanding H shares (excluding treasury shares) fell to 135.39 million, a 0.017% reduction from the prior day, while treasury shares increased to 0.83 million. Total issued shares remained unchanged at 136.22 million.

Since obtaining its current buyback mandate on 12 February 2026, HANXBIO-B has repurchased an aggregate 829,700 shares, equivalent to 0.61% of the 135.90 million shares outstanding when the mandate was granted. The board is authorised to repurchase up to 13.62 million shares under this mandate, leaving 12.79 million shares (approximately 94% of the limit) available for future buybacks.

Under Hong Kong listing rules, HANXBIO-B is restricted from issuing, selling or transferring any shares for 30 days following the latest repurchase, setting a moratorium until 26 June 2026.